Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 27;249(3):308–318. doi: 10.1002/path.5318

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

PATH-5318-FIG-0001-c — Pathological stage and grade, and expression of EGFR, CDH3, and KRT5 in the luminal subtypes. (A,B) Distribution of pathological stage and grade of the samples within each molecular subtype. (C) Representative IHC staining for EGFR and CDH3 for each molecular subtype. (D) Distribution of the combined basal markers EGFR, CDH3, and KRT5 expression patterns within each molecular subtype. Labels: 3, all markers show stratified expression; 2, two markers show stratified expression; 1, one marker shows stratified expression; diffuse, no marker shows stratified expression and at least one shows diffused staining; 0, all markers are negative. (E) The same data as in D divided into nonmuscle and muscle‐invasive cases for UroAp, UroC, and GU subtypes. UroA and UroB are excluded from this analysis due to low number of cases in one of the groups.